Review
Copyright ©The Author(s) 2023.
World J Clin Cases. Jun 16, 2023; 11(17): 3932-3948
Published online Jun 16, 2023. doi: 10.12998/wjcc.v11.i17.3932
Table 2 Selected data from available guidelines, systematic reviews, meta-analyses or clinical studies included in this review
Ref.
Type of study
Modality-ies studied
Summary of key points of each study
[2]Systematic review/meta-analysisLRT systemsLiver failure pathophysiology involves immune system over-activation and overproduction of proinflammatory cytokines, resulting in multiple-organ failure; reducing cytokine levels and thus correcting the dysregulation of the immune system is the pathophysiologic base of the application of LRT systems
Plasma exchangeThe best currently available LRT system in ACLF regarding 3-mo OS
[9]ReviewContinuous renal replacement therapyIt has indication for initiation of when ammonia is more than × 3 the uln, or more than 200 µmoles/L or when severe encephalopathy occurs
[10]ReviewContinuous renal replacement therapyIt has a role in the maintenance of circulatory, acid-base, and electrolyte balance during the pro-, peri-, and post-LT periods. It facilitates control of fluid balance and avoidance of volume overload/of peripheral edemas-ascites in patients with ALF and ACLF
[11]GuidelinesPlasma exchangeIt improves transplant-free survival in ALF, and modulates immune dysregulation; patients with early treatment initiation that will not undergo LT may benefit most
[19]ReviewAdsorption therapiesThey are delivered either by direct hemoperfusion or by plasma separation and subsequent plasma perfusion
Direct hemoperfusion (Cytosorb)It reduces levels of plasma bilirubin, ammonia, bile acids, and C-reactive protein and alters the immune response by absorbing proinflammatory cytokines; IL-6 has been identified as one of its main therapeutic targets; it presents high safety profile and easy application; indications, endpoints, effect on mortality and detection of which patients receive benefit from its use remain to be elucidated
[24]ReviewSingle-pass albumin dialysisDialysate’s ideal albumin concentration and flow rate are not standardized while there are no commercially available albumin-containing Continuous renal replacement therapy fluids. Metabolic disarrangements and loss of antibiotics have been observed
[30]Clinical studyHigh-volume hemofiltrationAn inexpensive and effective method that can be performed in every ICU or HDU, requiring no special equipment. Increased ultrafiltration rates enhance the elimination of ammonia
[35]Clinical studyHigh Cut-off membranesCytokine and toxin removal by these membranes may represent a promising intervention in ALF and ACLF
[36]ReviewAdsorption therapiesThey are delivered either as stand-alone or in combination with other extracorporeal modalities; the evidence to support their routine use is still conflicting and insufficient. May be of utmost benefit when applied early in the course, for an adequate duration, and frequently repeated until hemodynamic stability is achieved; they require carefully monitoring of drug levels, supplemented with additional doses as needed
[38]ReviewAdsorption therapiesThey have been used with positive effects in chronic dialysis and chronic liver disease
Direct hemoperfusion (Cytosorb)Ιt removes molecules up to 55 kDa
[43]Systematic review/meta-analysisDouble plasma molecular absorption systemIt combines two resins that remove macromolecules, medium-sized molecules, and toxins bound to plasma proteins, bilirubin, bile acids, ammonia, phenol, mercaptan, and inflammatory molecules
[44]Clinical studyDouble plasma molecular absorption systemIt is frequently combined with Plasma exchange therapy, to overcome loss of for albumin and coagulation factors, with promising results on survival rates
[48]Randomized controlled studyMolecular adsorbent recirculating systemIt removes albumin-bound molecules and decreases the plasma concentrations of bilirubin, ammonia, creatinine, urea, and cytokines. It has good safety profile
[49]ReviewMolecular adsorbent recirculating systemRecirculation of albumin dialysate restricts albumin loss; under certain circumstances and indications, it has been associated with hemodynamic and clinical improvement at patients with liver disease; dose adjustments and therapeutic drug monitoring, especially for low protein-bound antibiotics, is required
[50]Clinical studyMolecular adsorbent recirculating systemExpensive method, application in selected centers, but when compared to standard medical therapy alone it was found more cost-effective
[52,57]Review, Clinical studyPROMETHEUSIt performs albumin dialysis. It removes bilirubin, ammonia, creatinine, bile acids, amino acids, cytokines and is associated with a small reduction in plasma concentration of albumin; it was associated with improvement in HE
[54]Randomized controlled studyPROMETHEUSIt presents good safety profile and good hemodynamic tolerance
[67]Randomized controlled studyPROMETHEUSFavorable effect on patients’ subgroups such as those with more severe liver disease (MELD score > 30) and with type 1 HRS
[69]Randomized controlled studySingle-pass albumin dialysisIt is inexpensive, apart from the cost of albumin, and requires no special center for its application; it performs albumin dialysis and removes bilirubin, bile acids, urea and creatinine
[76]ReviewCoupled plasma filtration adsorptionIt combines plasma separation, adsorption and convection, with no loss of albumin or coagulation factors; it can effectively remove bilirubin, tryptophan, phenols, bile acids, cytokines
[77]Randomized controlled studyCoupled plasma filtration adsorptionIt cannot be performed in patients with septic shock
[87]ReviewPlasma exchangeIt improves 1- and 3-mo survival in nontransplanted patients. More pronounced effect and high level of evidence for high volume plasma exchange
[93]ReviewPlasma exchangeIt removes cytokines and albumin-bound toxins, and replaces plasma proteins; it effectively suppresses the inflammatory cascade of liver failure, while substituting clotting factors and correcting coagulation disorders; relatively expensive, it presents transfusion related side effects and cost